• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

3 months ago
Deals
Pharma

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

3 months ago
People
Pharma

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

3 months ago
Pharma
Law

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

3 months ago
R&D
Pharma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

3 months ago
Deals
Pharma

States sue Trump ad­min­is­tra­tion over bil­lions in NIH in­di­rect cost cuts

3 months ago
FDA+
Law

Trump’s tar­iff im­pact like­ly ‘min­i­mal’ for brand-name drug­mak­ers, man­u­fac­tur­ing part­ners

3 months ago
China
Pharma

Hims’ Su­per Bowl ad has drawn crit­i­cism from law­mak­ers — and now No­vo Nordisk

3 months ago
Pharma
Health Tech

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

3 months ago
R&D

Roivant dis­con­tin­ues lung dis­ease drug; Bio-Thera, In­tas make biosim­i­lar deal

3 months ago
News Briefing

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

3 months ago
Deals
Pharma

Pli­ant paus­es Phase 2b lung fi­bro­sis study af­ter safe­ty board rec­om­men­da­tion, shares plum­met

3 months ago
R&D

Ab­b­Vie wins FDA ap­proval for new an­tibi­ot­ic to treat com­plex in­tra-ab­dom­i­nal in­fec­tions

3 months ago
Pharma
FDA+

Q4 earn­ings up­dates; Bio­gen de­tails re­vised re­search strat­e­gy; RFK Jr. ad­vances out of Sen­ate com­mit­tee; and more

3 months ago
Weekly

Sen­a­tors ask FDA to dig in­to 'mis­lead­ing' Su­per Bowl ad from Hims

3 months ago
FDA+
Law

Post-Hoc: Chi­na ten­sions both help and hurt Il­lu­mi­na

3 months ago
China
Diagnostics

Sanofi, As­traZeneca back Teva's call to re­hear case on patent list­ings

3 months ago
Pharma
Law

Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

3 months ago
People
FDA+

A fourth per­son re­ceives gene-edit­ed pig kid­ney, first in three-per­son study 

3 months ago
R&D

Bel­gian reg­u­la­tor rec­om­mends block­ing In­di­an drug­mak­er's API pro­duc­tion

3 months ago
Pharma
Manufacturing

Up­dat­ed: Bay Area biotech VC to shut down 15 months af­ter launch, sources say, af­ter key in­vestor pulls out

3 months ago
People
Financing

Bain buys Mit­subishi Tan­abe Phar­ma in $3.3B bet on Japan

3 months ago
Deals
R&D

No­vo Nordisk takes aim at Roche in he­mo­phil­ia A, but is way be­hind

4 months ago
R&D

Long­time San­doz ex­ec an­nounces re­tire­ment; Lil­ly ap­points head of In­dia

4 months ago
Peer Review
First page Previous page 44454647484950 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times